DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment.
Previous studies found that marrow allografts from DLA-identical littermates resulted in survival of 60% of recipient dogs after an otherwise lethal dose of 450 cGy of total body irradiation (TBI), either because of successful allografts or autologous recovery after rejection of the allografts. Forty percent of dogs died with marrow aplasia after allograft rejection. The current study asked whether allogeneic engraftment could be enhanced and survival improved by treating allograft recipients with high doses of corticosteroids or with cyclosporine (CSP), administered either before or after transplantation. Five dogs in group 1 received corticosteroids beginning on day -5 and ending on day 32 after transplant. The starting dose was 12.5 mg of prednisone per kilogram orally twice daily. All five dogs rejected their allografts; three died early with marrow aplasia and two showed endogenous marrow recovery. Nine dogs received CSP from day -6 to day -1 before transplantation at a dose of 20 mg/kg/d intravenously administered in divided doses. All nine dogs rejected the marrow allograft; six died with marrow aplasia and three survived with endogenous marrow recovery. Seven dogs received CSP after transplantation at a dose of 30 mg/kg/d orally from day -1 to day 35. All seven had sustained allografts (two mixed chimeras and five complete donor-type chimeras) and became healthy long-term survivors without graft-versus-host disease. These results extend previous observations and confirm that grafts of marrow from DLA-identical littermates improved survival of dogs exposed to low but otherwise lethal doses of TBI. Additional therapy with high-dose corticosteroids administered peritransplantation and posttransplantation or CSP administered before transplantation neither enhanced the rate of allogeneic engraftment nor improved survival; however, CSP administered after transplantation resulted in successful allografts and event-free survival in all cases.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000379:methods*; D016572:Cyclosporine / Q000008:administration & dosage*; D004285:Dogs; D005260:Female; D006082:Graft Enhancement, Immunologic / Q000379:methods; D006085:Graft Survival / Q000187:drug effects / Q000528:radiation effects; D015395:Histocompatibility Antigens Class I; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008954:Models, Biological; D011241:Prednisone / Q000008:administration & dosage; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation / Q000379:methods*
D000305:Adrenal Cortex Hormones; D015395:Histocompatibility Antigens Class I; C039692:histocompatibility antigen DLA; D016572:Cyclosporine; D011241:Prednisone; D008775:Methylprednisolone